Cover Picture: The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R, 2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer (ChemMedChem 7/2013). Issue 7 (26th June 2013)

• Record Type: Journal Article
• Authors: Lücking, Ulrich; Jautelat, Rolf; Krüger, Martin; Brumby, Thomas; Lienau, Philip; Schäfer, Martina; Briem, Hans; Schulze, Julia; Hillisch, Alexander; Reichel, Andreas; Wengner, Antje Margret; Siemeister, Gerhard
• Is Part Of: ChemMedChem. Volume 8:Issue 7(2013:Jul.)
• Page Start: 1021
• Page End: 1021
• Publication Date: 2013-06-26
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201390025
• Languages: English
• ISSNs: 1860-7179

Abstract

<abstract abstract-type="graphical" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>The front cover picture shows</bold> the pan‐cyclin‐dependent kinase (CDK) inhibitor BAY 1000394 embedded in a schematic depiction of the cell cycle and a colored paraffin section of an untreated A2780Cis ovarian cancer tumor grown on a nude mouse. Aminopyrimdine BAY 1000394 is a balanced, orally available pan‐CDK inhibitor with potent, broad‐spectrum antiproliferative activity against human cancer cell lines, and is currently being investigated in a phase I clinical trial in patients with advanced solid tumors. For more details, see the Full Paper by Ulrich Lücking et al. on <ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">p. 1067 ff.</ext-link><boxed-text content-type="graphic" position="anchor" orientation="portrait"><graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgg22f67qt0" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></boxed-text></p> </abstract>